Compare Global X FTSE Southeast Asia ETF (ASEA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Novo Nordisk A/S — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while Novo Nordisk A/S trades at $49.17 (market cap $216.71B). The key difference: Novo Nordisk A/S pays a 3.64% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| ASEA | NVO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $20.65 | $71.70 |
52-Week Low | $16.31 | $35.29 |
Market Cap | — | $216.71B |
Enterprise Value | — | $235.67B |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
Novo Nordisk (NVO) trades at $49.48, up 1.23% today, with a bullish technical signal from moving averages and strong fundamentals including a 37.2% net income margin and 71.4% ROE. Recent earnings beats in Q3 2025-Q1 2026 highlight operational strength, while cash flow remains positive at $10.81B in 2025. The stock benefits from GLP-1 drug leadership, with oral Wegovy driving market expansion amid competitive pressures.
Outlook is positive with analyst consensus at 57.9% buy ratings, but risks include prescription slowdown concerns and rising debt-to-asset ratio to 22.54 in 2025. Investment appeal lies in robust profitability and growth in obesity/diabetes treatments, though investors should monitor competition and execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
